Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 14/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23937992 | 0.91 | JAK1 (0.49) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL23937990 | 0.91 | JAK2 (0.51) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL23937956 | 0.90 | TBK1 (0.41) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL30520757 | 0.90 | JAK1 (0.42) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL19779001 | 0.90 | JAK1 (0.42) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL19778620 | 0.89 | INSR (0.43) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL30520578 | 0.89 | INSR (0.43) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL30520519 | 0.88 | JAK1 (0.47) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL23937978 | 0.88 | JAK1 (0.41) | JAK1JAK2JAK3DGAT1INSR | |
| SCHEMBL19778623 | 0.88 | JAK1 (0.47) | JAK1JAK2JAK3DGAT1INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481824-B1 | 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-10-20 | — | — | EP | disclosed |